Replication stress induced by the ribonucleotide reductase inhibitor guanazole, triapine and gemcitabine in fission yeast. Issue 1 (9th March 2022)

• Record Type: Journal Article
• Authors: Alyahya, Mashael Y; Khan, Saman; Bhadra, Sankhadip; Samuel, Rittu E; Xu, Yong-jie
• Is Part Of: FEMS yeast research. Volume 22:Issue 1(2022)
• Publication Date: 2022-03-09
• Subjects: S. pombe -- ribonucleotide reductase -- hydroxyurea -- guanazole -- gemcitabine -- triapine -- the DNA replication checkpoint -- oxidative stress -- Rad3 -- Cds1 -- Chk1 -- genome stability; Yeast -- Periodicals; Yeasts -- Periodicals; 579.562
• DOI: 10.1093/femsyr/foac014
• Languages: English
• ISSNs: 1567-1356

Abstract

Abstract: Schizosaccharomyces pombe is an established yeast model for studying the cellular mechanisms conserved in humans, such as the DNA replication checkpoint. The replication checkpoint deals with replication stress caused by numerous endogenous and exogenous factors that perturb fork movement. If undealt with, perturbed forks collapse, causing chromosomal DNA damage or cell death. Hydroxyurea (HU) is an inhibitor of ribonucleotide reductase (RNR) commonly used in checkpoint studies. It produces replication stress by depleting dNTPs, which slows the movement of ongoing forks and thus activates the replication checkpoint. However, HU also causes side effects such as oxidative stress, particularly under chronic exposure conditions, which complicates the studies. To find a drug that generates replication stress more specifically, we tested three other RNR inhibitors gemcitabine, guanazole and triapine in S. pombe under various experimental conditions. Our results show that guanazole and triapine can produce replication stress more specifically than HU under chronic, not acute drug treatment conditions. Therefore, using the two drugs in spot assay, the method commonly used for testing drug sensitivity in yeasts, should benefit the checkpoint studies in S. pombe and likely the research in other model systems. Abstract : Effects of ribonucleotide reductase inhibitors on Schizosaccharomyces pombe .